Valuation : vTv Therapeutics Inc.

Market Cap 405M 347M 325M 298M 561M 38.64B 562M 3.85B 1.51B 19.48B 1.52B 1.49B 64.46B P/E 2026 *
-14.5x
P/E 2027 * -8.28x
Enterprise Value 405M 347M 325M 298M 561M 38.64B 562M 3.85B 1.51B 19.48B 1.52B 1.49B 64.46B EV / Sales 2026 *
15.5x
EV / Sales 2027 * -
Free-Float
61.17%
Yield 2026 *
-
Yield 2027 * -
1 day-2.29%
1 week-0.85%
Current month+1.39%
1 month+5.74%
3 months-2.73%
6 months-14.05%
Current year-17.98%
1 week 32.56
Extreme 32.565
34.76
1 month 28.76
Extreme 28.7579
36.52
Current year 28.75
Extreme 28.75
44
1 year 17
Extreme 17.0001
44
3 years 7.38
Extreme 7.38
44
5 years 7.38
Extreme 7.38
86.8
10 years 7.38
Extreme 7.38
336
Manager TitleAgeSince
Chief Executive Officer 68 2022-07-31
Director of Finance/CFO 50 2025-05-18
Chief Tech/Sci/R&D Officer - 2023-11-01
Director TitleAgeSince
Director/Board Member 56 2020-11-15
Director/Board Member 48 2022-07-10
Chairman 68 2024-02-29
Date Insider Type Main position Quantity % Market Cap.
6/26/26 Free

Director

6,000 0.1523%
2/17/26 Free

Chief Financial Officer

44,969 1.1419%
2/17/26 Free

Chief Executive Officer

140,000 3.5551%
Change 5-day change 1-year change 3-year change Capi.($)
-2.29%-0.85%+101.97%+62.41% 417M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.39% 65.4B
-1.03%+0.46%+8.14%-5.28% 28.28B
0.00%+1.73%+59.01%+13.87% 26.57B
-2.41%-2.95%-9.77%+455.82% 27.16B
+0.37%+1.21%+36.55%-15.78% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%-1.59%+13.19%+520.34% 15.87B
-1.50%+2.92%+43.50%+151.30% 13.9B
Average -0.12%+1.43%+63.24%+180.00% 28.87B
Weighted average by Cap. +0.75%+0.94%+56.12%+154.97%

Financials

2026 *2027 *
Net sales 26.08M 22.39M 20.96M 19.19M 36.15M 2.49B 36.26M 248M 97.02M 1.26B 97.92M 95.8M 4.15B -
Net income -28.12M -24.14M -22.6M -20.69M -38.98M -2.69B -39.09M -268M -105M -1.35B -106M -103M -4.48B -58.42M -50.15M -46.95M -42.99M -80.99M -5.58B -81.22M -556M -217M -2.81B -219M -215M -9.31B
Net Debt - -
Logo vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Employees
26
Date Price Change Volume
26-08-27 US$32.80 -2.29% 58,434
26-08-26 US$33.57 -1.00% 117,244
26-08-25 US$33.91 +0.06% 59,297
26-08-24 US$33.89 +1.91% 17,997
26-08-21 US$33.26 +0.53% 26,674
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
32.80USD
Average target price
53.83USD
Spread / Average Target
+64.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VTVT Stock